Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Proposes 2-Stage Discussions on Cost-Effective Assessment of Medical Technologies
June 29, 2012
- JPO Rules Actonel Patent Invalid; Ajinomoto Considering Appeal
June 29, 2012
- MHLW Talks to Drug Makers with Facilities Eligible for Exemption from Planned Power Outages
June 27, 2012
- Targets for Generic Drug Use Should Be Included in Medical Expenditure Optimization Plan: Mr Konishi of DPJ
June 26, 2012
- MHLW Orders Updates from Chugai Following Criticism for Reporting Deficiencies by Roche in US
June 26, 2012
- MHLW Approves 11 Products Including Additional Indication for Lyrica
June 26, 2012
- Median Review Time Down by About Half Since FY2007: PMDA
June 25, 2012
- Antipyretic/Analgesics Are Most Common Cause for Relief Benefits for Damage from ADRs: PMDA
June 25, 2012
- PMDA Adopts New Rule for Staff Re-Employment Effective This Month, No Uses Made Yet
June 25, 2012
- 166 Applications Received for Preliminary Interviews for Regulatory Strategy Consultation in First 9 Months: PMDA
June 25, 2012
- Claims of “Ineffective” Generics Might Be Due to Placebo Effect in Some Cases: Mr Yoshida of HIB
June 25, 2012
- MHLW to Strengthen Focus on Dementia with Budget Request for FY2013
June 22, 2012
- MHLW to Draft New Guidelines on Pharmacotherapy for Dementia
June 22, 2012
- Nichi-Iko No. 1 in Terms of the Number of Generics Listed in June; Pfizer at 4th
June 22, 2012
- 60% Rule Applied for 3 APIs in June’s Generic Listing
June 22, 2012
- Access System for Unapproved Drugs to Be Submitted at Next Ordinary Diet Session “at the Latest”: Mr Kawai of DPJ
June 21, 2012
- MHLW Calls for OTC Switch for Hyaluronate Sodium
June 21, 2012
- Establishment of Third-Party Organization “Historical”: DPJ Member Kawai
June 20, 2012
- PMDA’s Science Committee Holds 1st Meeting; Will Work to Improve Review Quality through Exchanges with Researchers
June 20, 2012
- MHLW Committee Compiles Discussion Points on System for Public Release of Drug Damage Documents
June 20, 2012
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…